Lyra Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OTC.Pink
Lyra Therapeutics reports substantial doubt about its ability to continue as a going concern, despite positive Phase 3 ENLIGHTEN 2 trial results, following a major workforce reduction and a prior trial failure.
OTC.Pink
Lyra Therapeutics reported positive Phase 3 ENLIGHTEN 2 trial results for LYR-210, significantly reducing its net loss in Q2 2025 while addressing going concern doubts and securing new financing.
OTC.Pink
Lyra Therapeutics faces going concern doubts as it reports Q1 2025 results following a restructuring and strategic review after a failed Phase 3 trial.
OTC.Pink
Lyra Therapeutics' Phase 3 ENLIGHTEN 1 trial for LYR-210 failed to meet its primary endpoint, leading to a significant restructuring and workforce reduction.
OTC.Pink
Lyra Therapeutics' Phase 3 ENLIGHTEN 1 trial for LYR-210 failed to meet its primary endpoint, leading to a significant restructuring and workforce reduction.
OTC.Pink
Lyra Therapeutics reports a net loss of $22.45 million for the first quarter of 2024, while continuing to advance its clinical programs.